PaxVax Inc:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】PaxVax Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C10882)・商品コード:DATA904C10882
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:34
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
PaxVax Inc (PaxVax) is a vaccine company that develops and commercializes specialty vaccines against infectious diseases. The company develops scalable, and oral vaccines. Its activities include early-stage preclinical research and development, clinical study support, drug product manufacturing, drug substance sterile fill and finish, and packaging infrastructure. PaxVax commercializes vaccines for cholera, HIV, zika, endemic infectious diseases, chikungunya, hepatitis A, adenovirus and dengue. The company’s vector vaccines are based on adenovirus serotypes 4 and 7 and the A549 cell substrate. It operates through its laboratory and manufacturing facilities located in San Diego, California; and Thorishaus, Switzerland. PaxVax is headquartered in Redwood City, California, the US.

PaxVax Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PaxVax Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PaxVax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
PaxVax Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
PaxVax Acquires Vivotif from Crucell 10
Venture Financing 11
PaxVax Raises USD12 Million in Extended Series B Financing 11
PaxVax Raises USD50 Million in Venture Debt Financing 12
PaxVax Raises US$6 Million In Venture Financing 13
PaxVax Raises US$22 Million In Series B Financing 14
Private Equity 15
Cerberus Capital Invests USD105 Million in PaxVax 15
Partnerships 16
PaxVax and TerahVax Korea Enter into Distribution Agreement 16
PaxVax Enters into Distribution Agreement with Seqirus 17
Valneva Enters into Distribution Agreement with PaxVax 18
PaxVax Enters into Distribution Agreement with Novartis 19
PaxVax Enters into Distribution Agreement with BioCSL 20
PaxVax Enters into Distribution Agreement with Valneva 21
Licensing Agreements 22
PaxVax Enters into Licensing Agreement with National Institutes of Health 22
PaxVax Enters into Licensing Agreement with Leukocare 23
PaxVax Enters into Licensing Agreement with University Of California, San Diego 24
Acquisition 25
Emergent BioSolutions Acquires PaxVax from Cerberus Capital Management for USD270 Million 25
PaxVax Inc – Key Competitors 27
PaxVax Inc – Key Employees 28
PaxVax Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Government and Public Interest 30
Jun 29, 2018: Same Vaccine Concept for Ebola Appears Effective Against Nipah Virus 30
Clinical Trials 31
May 04, 2018: FDA Grants PaxVax Fast Track Designation for its Chikungunya Vaccine 31
Apr 25, 2018: PaxVax Announces the Initiation of Phase 2b Trial for its Chikungunya Vaccine 32
May 08, 2017: PaxVax Initiates Clinical Trials of a Modernized Adenovirus Vaccine in Collaboration with the U.S. Army Medical Materiel Development Activity and the Walter Reed Army Institute of Research to Protect U.S. Military Personnel 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
PaxVax Inc, Pharmaceuticals & Healthcare, Key Facts 2
PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PaxVax Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PaxVax Inc, Deals By Therapy Area, 2012 to YTD 2018 8
PaxVax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
PaxVax Acquires Vivotif from Crucell 10
PaxVax Raises USD12 Million in Extended Series B Financing 11
PaxVax Raises USD50 Million in Venture Debt Financing 12
PaxVax Raises US$6 Million In Venture Financing 13
PaxVax Raises US$22 Million In Series B Financing 14
Cerberus Capital Invests USD105 Million in PaxVax 15
PaxVax and TerahVax Korea Enter into Distribution Agreement 16
PaxVax Enters into Distribution Agreement with Seqirus 17
Valneva Enters into Distribution Agreement with PaxVax 18
PaxVax Enters into Distribution Agreement with Novartis 19
PaxVax Enters into Distribution Agreement with BioCSL 20
PaxVax Enters into Distribution Agreement with Valneva 21
PaxVax Enters into Licensing Agreement with National Institutes of Health 22
PaxVax Enters into Licensing Agreement with Leukocare 23
PaxVax Enters into Licensing Agreement with University Of California, San Diego 24
Emergent BioSolutions Acquires PaxVax from Cerberus Capital Management for USD270 Million 25
PaxVax Inc, Key Competitors 27
PaxVax Inc, Key Employees 28
PaxVax Inc, Other Locations 29

List of Figures
PaxVax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PaxVax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PaxVax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[PaxVax Inc:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C10882)販売に関する免責事項を必ずご確認ください。
★調査レポート[PaxVax Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆